BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Aurobindo Pharma Ltd.’s nine months performance was weak, given cost headwinds and lower U.S. sales. We believe cost pressures have stabilised and margin trajectory should improve from FY23.
However, pick up in U.S. sales hinge on timely niche approvals along with stabilisation of pricing pressure in base business.
Aurobindo Pharma has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and production linked incentive, which are expected to be reflected from H2FY23.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
POPULAR